1. Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings.
- Author
-
Tanabe K, Hoye A, Lemos PA, Aoki J, Arampatzis CA, Saia F, Lee CH, Degertekin M, Hofma SH, Sianos G, McFadden E, Smits PC, van der Giessen WJ, de Feyter P, van Domburg RT, and Serruys PW
- Subjects
- Angioplasty, Balloon, Coronary, Coronary Angiography, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease drug therapy, Coronary Artery Disease pathology, Coronary Restenosis diagnostic imaging, Coronary Restenosis pathology, Female, Florida, Humans, Incidence, Male, Middle Aged, Registries, Treatment Outcome, Coronary Artery Disease therapy, Coronary Restenosis mortality, Immunosuppressive Agents administration & dosage, Sirolimus administration & dosage, Stents
- Abstract
The percutaneous treatment of coronary bifurcation stenoses is hampered by an increased rate of subsequent restenosis. The present study reports on the outcomes of a consecutive series of 58 patients with 65 de novo bifurcation stenoses treated with sirolimus-eluting stent implantation in both the main vessel and side branch. At 6 months, the incidence of major adverse cardiac events was 10.3% (1 death and 5 target lesion revascularizations) with no episodes of acute myocardial infarction or stent thrombosis.
- Published
- 2004
- Full Text
- View/download PDF